Selected Publications

Carter J, von Reusner JM, Sellmyer MA, Bagg A, Barta SK: Common Lymphoma in an Uncommon Location. Am J Hematol 100(8): 1437-1439, August 2025.

Dave NK, Carvajal V, Watts AC, Carter JS, Cook M, Thomas C, Tsai DE, Schuster SJ, Gerson JN, Barta SK, Svoboda J, Chong EA, Hwang WT, Landsburg DJ, Nasta SD.: Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma. Blood Neoplasia 16(2), April 2025.

Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK.: Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2025.

Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol 2025.

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2025.

Omar Elghawy, Miao Cao, Jason Xu, Daniel J Landsburg, Jakub Svoboda, Sunita D Nasta, Elise A Chong, Stephen J Schuster, Colin J Thomas, Jordan S Carter, Montreh Tavakkoli, Marco Ruella, Stefan K Barta: Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas. Cancers (Basel) 16(19): 3430, Oct 2024.

Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, Chong EA, Gabrielli G, Nasta SD, Landsburg DJ, Carter J, Pajarillo R, Barta SK, White G, Weber E, Napier E, Porter DL, Garfall AL, Schuster SJ, Ruella M.: Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. Journal of Hematology & Oncology 17(1): 19, April 2024.

Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton R, Pajarillo R, Patel V, White G, Ballard HJ, Weber E, Napier E, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O'Connor R, Schuster SJ, Ruella M.: Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Advances 8(3): 653, Feb 2024.

Elghawy O, Cao M, Xu J, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Tavakkoli M, Ruella M, Barta SK.: Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas. Cancers 2024.

Kevin A David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer 5, Mary-Kate Malecek 6, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean Alyxa Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, David A Bond, Prashasti Agrawal, Angel Mier-Hicks 2, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A Goldlust, Matthew Folstad, Pallavi Kumar, Thomas A Ollila, Johnny Cai, Stephen Spurgeon, Alex Sieg, Joseph Cleveland, Julie Chang, Narendranath Epperla, Reem Karmali, Seema Naik, Peter Martin, Sonali M Smith, James Rubenstein, Brad Kahl, Andrew M Evens: Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. American Journal of Hematology 98(6): 900-912, Apr 2023.